Mitchell Harris London

Mitchell is an investment director at Hakluyt Capital, having joined Hakluyt in 2021.

Prior to Hakluyt, he worked in venture and growth-stage biotechnology companies, including as chief strategy officer and general manager at Genomics plc and Global Head of Emerging Business Lines at Abcam (later acquired by Danaher Corporation). Before then, he was a consultant in the Pharmaceutical and Medical Products Practice at McKinsey & Co., where he supported corporate and investor clients on strategy and transactions, a principal at QuantumBlack (AI by McKinsey), and an official in the UK Cabinet Office where he focused on life sciences and healthcare policy.